about
Drug delivery to posterior intraocular tissues: third Annual ARVO/Pfizer Ophthalmics Research Institute Conference.Intrascleral drug delivery to the eye using hollow microneedles.Influence of permeant lipophilicity on permeation across human scleraIontophoresis: a potential emergence of a transdermal drug delivery system.Recent advances in ophthalmic drug delivery.Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications.The rule of five for non-oral routes of drug delivery: ophthalmic, inhalation and transdermalTranssclera Drug Delivery by Pulsed High-Intensity Focused Ultrasound (HIFU): An Ex Vivo Study.Sustained release micellar carrier systems for iontophoretic transport of dexamethasone across human sclera.A flexible device for ocular iontophoretic drug delivery.Quantitative analysis of iontophoretic drug delivery from micropipettes.Transungual iontophoretic transport of polar neutral and positively charged model permeants: effects of electrophoresis and electroosmosis.Sustained transscleral drug delivery.Safety evaluation of ocular drug delivery formulations: techniques and practical considerations.Non-invasive gene transfer by iontophoresis for therapy of an inherited retinal degenerationInfluence of drug lipophilicity on drug release from sclera after iontophoretic delivery of mixed micellar carrier system to human sclera.Evaluation of tissue interactions with mechanical elements of a transscleral drug delivery device.Drug delivery systems for the eye.Diagnostic and therapeutic applications of iontophoresis.Iontophoretic drug delivery across the nail.Nanomaterials for ocular drug delivery.Delivery systems and local administration routes for therapeutic siRNA.Advances in the understanding of retinal drug disposition and the role of blood-ocular barrier transporters.Contact lenses as a platform for ocular drug delivery.Challenges and solutions in topical ocular drug-delivery systems.Progressive development in experimental models of transungual drug delivery of anti-fungal agents.Assessment of trans-scleral iontophoresis delivery of lutein to the human retina.Established and emerging ancillary techniques in management of microbial keratitis: a review.Extended ocular drug delivery systems for the anterior and posterior segments: biomaterial options and applications.Iontophoretic transport of charged macromolecules across human sclera.Examination of penetration routes and distribution of ionic permeants during and after transscleral iontophoresis with magnetic resonance imagingEffective electrophoretic mobilities and charges of anti-VEGF proteins determined by capillary zone electrophoresisExamination of barriers and barrier alteration in transscleral iontophoresis.Evaluation of Intrastromal Riboflavin Concentration in Human Corneas after Three Corneal Cross-Linking Imbibition Procedures: A Pilot Study.Electrically assisted delivery of macromolecules into the corneal epithelium.In-vitro permeation of bevacizumab through human sclera: effect of iontophoresis application.Transcorneal iontophoresis for delivery of ciprofloxacin hydrochloride.In vitro and in vivo evaluation of carboplatin delivery to the eye using hydrogel-iontophoresis.Pharmacodynamic profile of mydriatic agents delivered by ocular piezo-ejection microdosing compared with conventional eyedropper.Keratoconus Treatment Algorithm.
P2860
Q30487756-8C396896-DA23-4906-89DB-B6CD0C4D50E5Q33978350-0614D365-B477-4008-A591-2745CB05D2C2Q34233208-CEEA4665-E227-466E-9E9B-6CB084598534Q34259364-2CB81F00-9CFB-45A2-B442-8BCF3713D5DBQ34636338-3A3EF525-0944-4868-A9B4-2A20DA59F852Q34701929-A6693358-9288-43DB-8C0C-0DED676BBEA6Q34778919-EFB9931B-6D92-4289-B0E0-6974395AF0C8Q35403847-5F25CBC1-FBFE-4431-8353-539CFAA65476Q36024067-70C98B35-A0EA-42F8-9ED9-95231E0AED7BQ36624878-13CAF396-E7C5-4508-894E-E05398A14407Q36665292-4AC96DBB-6135-40D4-915F-BC8B53B5FA46Q36915052-E39DF25C-107D-46A5-A329-B6172683317FQ37039016-6A447B82-C31C-421F-AFB7-ECA405E356A2Q37109083-8E74776B-34AD-4D4D-8EC6-00F3B23EC8D4Q37268483-C972D1F9-D05D-4A10-B5EB-D8B6821BAD09Q37274226-C1F158E2-7329-44B8-B397-B4628B366E52Q37327804-99FE91F8-C47D-474E-A6BF-59099C59F698Q37472106-07644AD7-BED1-4153-9673-040960B75CF1Q37618810-67F70328-608D-4714-8C1F-969639A34FBDQ37965619-0E37D1AB-8243-4A4A-9B6D-E6FC803A6EBFQ38003088-AE6B8D68-D0E4-4307-8032-A1181F1BDBC9Q38076344-92602FE3-3788-40D0-AEE4-CCDA158F7A05Q38104396-00C814B8-0E6B-4D33-899B-DA6F81B58B6FQ38123230-B0668176-8C25-47F7-954A-521AA358273FQ38177335-AEFD9990-AEBA-4D10-A95A-25C426551D35Q38446060-D7410B52-302E-432A-AC0F-87029754D5E1Q38658699-E17FB145-8FA1-4D7B-8166-84BB190EE24BQ38738334-942E9AE2-8275-41CE-A919-E31AC09EA7C6Q38934604-EAF84173-D4E4-4CA3-8927-1B1329AC93C7Q39623649-BAFE401A-8C01-477E-BF9A-A56CBBAD8A56Q41434956-401BA577-034C-48D1-8A57-F50AFC4D9EF8Q41856804-75CCDF9E-DD27-4C51-BABD-1E17CFE5EF30Q41891987-06D617D8-77E9-403A-9492-717B8558323AQ42207463-FBFF8F44-C82D-4E5D-9495-D2C13DA04278Q42914104-6E0CB009-1212-41B9-88DE-6972A4BB3C89Q42925005-03FE3E11-18F9-412B-88A1-7C9B99344FB0Q46433997-66836AB7-5CB6-4342-8DE3-F2E364083A8BQ46694027-662073E2-19AD-49C9-85A9-A7E5CED3BC0BQ46968848-237CC37A-4AAF-4184-85B5-A787FB6508B2Q47096888-8C5F62B0-5088-4F71-885E-03451981FBE9
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Iontophoresis: a non-invasive ocular drug delivery.
@ast
Iontophoresis: a non-invasive ocular drug delivery.
@en
type
label
Iontophoresis: a non-invasive ocular drug delivery.
@ast
Iontophoresis: a non-invasive ocular drug delivery.
@en
prefLabel
Iontophoresis: a non-invasive ocular drug delivery.
@ast
Iontophoresis: a non-invasive ocular drug delivery.
@en
P1476
Iontophoresis: a non-invasive ocular drug delivery
@en
P2093
Esther Eljarrat-Binstock
P304
P356
10.1016/J.JCONREL.2005.09.049
P407
P577
2005-12-15T00:00:00Z